Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

摘要: Background: Selecting patients according to key genetic characteristics may help tailor chemotherapy and optimize the treatment in non-small cell lung cancer (NSCLC). Genetic variations drug metabolism affect clinical response, toxicity, prognosis of NSCLC treated with cisplatin/gemcitabine-based therapy. Patients Methods: We evaluated seven single-nucleotide polymorphisms six genes CDA Lys27Gln (A/C); C435T ; ERCC1 C118T XRCC3 Thr241Met (C/T); XPD Lys751Gln P53 Arg72Pro (G/C), RRM1 C524T 192 chemotherapy-naive advanced regimen by TaqMan probe-based assays 7300 Real-Time PCR System, using genomic DNA extracted from blood samples. Results: The 435 T/T genotype was significantly associated better response ( p = 0.03). C/T a increased risk nonhematological toxicity grade ≥3 0.02) after adjusting for performance status, age, type regimen. In multivariate Cox model, 751 C/C significant prognostic factor longer progression-free survival 0.006). Conclusion: Our data suggest polymorphic metabolic gene were therapy NSCLC.